Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade.
Anastasiou P, Moore C, Rana S, Tomaschko M, Pillsbury CE, de Castro A, Boumelha J, Mugarza E, de Carné Trécesson S, Mikolajczak A, Blaj C, Goldstone R, Smith JAM, Quintana E, Molina-Arcas M, Downward J. Anastasiou P, et al. Among authors: rana s. Nat Commun. 2024 Sep 25;15(1):8146. doi: 10.1038/s41467-024-52324-3. Nat Commun. 2024. PMID: 39322643 Free PMC article.
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
Coelho MA, de Carné Trécesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, East P, Spencer-Dene B, Nye E, Barnouin K, Snijders AP, Lai WS, Blackshear PJ, Downward J. Coelho MA, et al. Among authors: rana s. Immunity. 2017 Dec 19;47(6):1083-1099.e6. doi: 10.1016/j.immuni.2017.11.016. Epub 2017 Dec 12. Immunity. 2017. PMID: 29246442 Free PMC article.
RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.
Lionarons DA, Hancock DC, Rana S, East P, Moore C, Murillo MM, Carvalho J, Spencer-Dene B, Herbert E, Stamp G, Damry D, Calado DP, Rosewell I, Fritsch R, Neubig RR, Molina-Arcas M, Downward J. Lionarons DA, et al. Among authors: rana s. Cancer Cell. 2019 Jul 8;36(1):68-83.e9. doi: 10.1016/j.ccell.2019.05.015. Epub 2019 Jun 27. Cancer Cell. 2019. PMID: 31257073 Free PMC article.
Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry.
van Maldegem F, Valand K, Cole M, Patel H, Angelova M, Rana S, Colliver E, Enfield K, Bah N, Kelly G, Tsang VSK, Mugarza E, Moore C, Hobson P, Levi D, Molina-Arcas M, Swanton C, Downward J. van Maldegem F, et al. Among authors: rana s. Nat Commun. 2021 Oct 8;12(1):5906. doi: 10.1038/s41467-021-26214-x. Nat Commun. 2021. PMID: 34625563 Free PMC article.
Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.
Mugarza E, van Maldegem F, Boumelha J, Moore C, Rana S, Llorian Sopena M, East P, Ambler R, Anastasiou P, Romero-Clavijo P, Valand K, Cole M, Molina-Arcas M, Downward J. Mugarza E, et al. Among authors: rana s. Sci Adv. 2022 Jul 22;8(29):eabm8780. doi: 10.1126/sciadv.abm8780. Epub 2022 Jul 20. Sci Adv. 2022. PMID: 35857848 Free PMC article.
An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.
Boumelha J, de Carné Trécesson S, Law EK, Romero-Clavijo P, Coelho MA, Ng KW, Mugarza E, Moore C, Rana S, Caswell DR, Murillo M, Hancock DC, Argyris PP, Brown WL, Durfee C, Larson LK, Vogel RI, Suárez-Bonnet A, Priestnall SL, East P, Ross SJ, Kassiotis G, Molina-Arcas M, Swanton C, Harris R, Downward J. Boumelha J, et al. Among authors: rana s. Cancer Res. 2022 Oct 4;82(19):3435-3448. doi: 10.1158/0008-5472.CAN-22-0325. Cancer Res. 2022. PMID: 35930804 Free PMC article.
2,461 results